D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL)

D. Boral Capital reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note published on Monday morning,Benzinga reports. They currently have a $46.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Anavex Life Sciences in a report on Monday, November 4th.

Anavex Life Sciences Stock Down 0.1 %

NASDAQ AVXL opened at $9.03 on Monday. The company has a market cap of $765.74 million, a price-to-earnings ratio of -18.06 and a beta of 0.60. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $10.45. The business has a 50 day moving average price of $6.61 and a 200-day moving average price of $5.65.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AVXL. Nwam LLC purchased a new position in Anavex Life Sciences in the third quarter worth $5,172,000. Renaissance Technologies LLC raised its stake in shares of Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 386,537 shares during the period. Deerfield Management Company L.P. Series C bought a new stake in shares of Anavex Life Sciences in the second quarter valued at $346,000. Barclays PLC raised its stake in shares of Anavex Life Sciences by 70.4% in the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after buying an additional 64,101 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Anavex Life Sciences by 1.2% in the first quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock valued at $22,471,000 after buying an additional 54,034 shares during the period. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.